This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Jul;96(1):1-5.

doi: 10.1016/j.radonc.2010.06.001. Epub 2010 Jun 19.

Fractionation in prostate cancer--is it time after all?

Michael Baumann, Tobias Hölscher, Jim Denham

PMID: 20566227
DOI: 10.1016/j.radonc.2010.06.001

Editorial

Fractionation in prostate cancer--is it time after all?

Michael Baumann et al. Radiother Oncol. 2010 Jul.

. 2010 Jul;96(1):1-5.

doi: 10.1016/j.radonc.2010.06.001. Epub 2010 Jun 19.

Authors

Michael Baumann, Tobias Hölscher, Jim Denham

PMID: 20566227
DOI: 10.1016/j.radonc.2010.06.001

No abstract available

PubMed Disclaimer

Comment on

The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.
Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Thames HD, et al. Radiother Oncol. 2010 Jul;96(1):6-12. doi: 10.1016/j.radonc.2010.03.020. Epub 2010 Apr 17. Radiother Oncol. 2010. PMID: 20400191

Similar articles

The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.
Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Thames HD, et al. Radiother Oncol. 2010 Jul;96(1):6-12. doi: 10.1016/j.radonc.2010.03.020. Epub 2010 Apr 17. Radiother Oncol. 2010. PMID: 20400191
Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V. Lettmaier S, et al. Radiother Oncol. 2012 Aug;104(2):181-6. doi: 10.1016/j.radonc.2012.07.003. Epub 2012 Jul 30. Radiother Oncol. 2012. PMID: 22853851 Clinical Trial.
Dose escalation in localized prostate cancer: make no assumptions.
Zietman AL. Zietman AL. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):635-6. doi: 10.1016/s0360-3016(02)02978-4. Int J Radiat Oncol Biol Phys. 2002. PMID: 12377310 No abstract available.
[Immediate or delayed postoperative radiotherapy in prostate cancer].
Carrie C, Pommier P. Carrie C, et al. Cancer Radiother. 2005 Nov;9(6-7):379-81. doi: 10.1016/j.canrad.2005.09.006. Epub 2005 Oct 19. Cancer Radiother. 2005. PMID: 16236539 Review. French.
Clinical assessment of outcome of prostate cancer (TCP, NTCP).
Perez CA, Michalski J, Mansur D. Perez CA, et al. Rays. 2005 Apr-Jun;30(2):109-20. Rays. 2005. PMID: 16294903 Review.

See all similar articles

Cited by

Hypofractionated radiotherapy for localized prostate cancer.
Höcht S, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Hölscher T, Martin T, Sedlmayer F, Wenz F, Zips D, Wiegel T. Höcht S, et al. Strahlenther Onkol. 2017 Jan;193(1):1-12. doi: 10.1007/s00066-016-1041-5. Epub 2016 Sep 14. Strahlenther Onkol. 2017. PMID: 27628966 Free PMC article.
Protons, Photons, and the Prostate - Is There Emerging Evidence in the Ongoing Discussion on Particle Therapy for the Treatment of Prostate Cancer?
Schiller KC, Habl G, Combs SE. Schiller KC, et al. Front Oncol. 2016 Jan 28;6:8. doi: 10.3389/fonc.2016.00008. eCollection 2016. Front Oncol. 2016. PMID: 26858936 Free PMC article. Review.
Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer.
Wolf F, Sedlmayer F, Aebersold D, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Ghadjar P, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Schmidt-Hegemann NS, Zamboglou C, Zips D, Wiegel T. Wolf F, et al. Strahlenther Onkol. 2021 Feb;197(2):89-96. doi: 10.1007/s00066-020-01723-8. Epub 2020 Dec 10. Strahlenther Onkol. 2021. PMID: 33301049 Free PMC article. Review.
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Oehus AK, Kroeze SGC, Schmidt-Hegemann NS, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Belka C, Combs SE, Grosu AL, Müller AC, Guckenberger M, Christiansen H, Henkenberens C. Oehus AK, et al. BMC Cancer. 2020 Apr 29;20(1):362. doi: 10.1186/s12885-020-06883-5. BMC Cancer. 2020. PMID: 32349700 Free PMC article.
Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?
Vogelius IR, Bentzen SM. Vogelius IR, et al. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):89-94. doi: 10.1016/j.ijrobp.2012.03.004. Epub 2012 May 30. Int J Radiat Oncol Biol Phys. 2013. PMID: 22652106 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information